Passage Bio (PASG) News Today $0.51 +0.03 (+6.20%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Le titre de Passage Bio atteint un plus bas de 52 semaines à 0,54 $ face aux défis du marchéNovember 16, 2024 | fr.investing.comTD Cowen Keeps Their Buy Rating on Passage Bio (PASG)November 15, 2024 | markets.businessinsider.comPassage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference!November 8, 2024 | msn.comPassage Bio to Present at Guggenheim Securities Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comPassage Bio présente des avancées dans la thérapie génique pour la démenceOctober 25, 2024 | fr.investing.comPassage Bio delivered preclinical, interim data at ESGCTOctober 25, 2024 | markets.businessinsider.comPassage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual ConferenceOctober 24, 2024 | globenewswire.comLe titre de Passage Bio atteint un plus bas de 52 semaines à 0,55$ face aux défis du marchéOctober 17, 2024 | fr.investing.comLe cours de l'action Passage Bio atteint un plus bas de 52 semaines à 0,57 $ face aux défis du marchéOctober 7, 2024 | fr.investing.comPassage Bio (NASDAQ:PASG) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPassage Bio’s CEO to Present at Prestigious Genetic Medicines ConferenceSeptember 25, 2024 | msn.comOrbimed Advisors LLC Adjusts Stake in Passage Bio IncSeptember 25, 2024 | finance.yahoo.comPassage Bio to Present at Chardan’s 8th Annual Genetic Medicines ConferenceSeptember 23, 2024 | finance.yahoo.comPassage Bio to Present at Chardan's 8th Annual Genetic Medicines ConferenceSeptember 23, 2024 | globenewswire.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 25,631 SharesSeptember 19, 2024 | insidertrades.comOrbimed Advisors LLC Reduces Stake in Passage Bio IncSeptember 19, 2024 | finance.yahoo.comOptimistic Buy Rating for Passage Bio as PBFT02 Shows Promising Results and Market PotentialSeptember 18, 2024 | markets.businessinsider.comCanaccord voit un potentiel dans l'action de Passage Bio suite aux données positives de l'essai de phase 1/2September 17, 2024 | fr.investing.comPassage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic VisionSeptember 12, 2024 | msn.comPassage Bio nomme un nouveau directeur et accorde des options sur actionsSeptember 11, 2024 | fr.investing.comPassage Bio Welcomes Tom Kassberg to Board of DirectorsSeptember 10, 2024 | globenewswire.comPassage Bio prévoit des coûts de dépréciation de 3,5 à 5,5 millions de dollarsSeptember 9, 2024 | fr.investing.comRodman & Renshaw Initiates Coverage of Passage Bio (PASG) with Buy RecommendationSeptember 4, 2024 | msn.comPassage Bio to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 30, 2024 | globenewswire.comPassage Bio Reports Q2 2024 Financial Results and Business UpdatesAugust 10, 2024 | msn.comPassage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsAugust 8, 2024 | globenewswire.comPassage Bio risque d'être radiée de la cote du Nasdaq en raison du prix de son actionAugust 3, 2024 | fr.investing.comPassage Bio Out-Licenses Rare Disease Programs to GEMMA BiotherapeuticsAugust 3, 2024 | msn.comPassage Bio gains after licensing deal with GEMMA BioAugust 1, 2024 | msn.comPassage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research CollaborationAugust 1, 2024 | globenewswire.comPassage Bio (NASDAQ:PASG) Shares Down 4.3% Passage Bio (NASDAQ:PASG) Stock Price Down 4.3%July 24, 2024 | marketbeat.comExpanding Market and Promising Preclinical Results Bolster Buy Rating for Passage BioJuly 20, 2024 | markets.businessinsider.comPassage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 PatientsJuly 16, 2024 | globenewswire.comPassage Bio to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceJune 5, 2024 | globenewswire.comFY2024 Earnings Estimate for Passage Bio, Inc. Issued By Chardan Capital (NASDAQ:PASG)Passage Bio, Inc. (NASDAQ:PASG - Free Report) - Equities research analysts at Chardan Capital raised their FY2024 earnings per share estimates for Passage Bio in a report released on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now anticipates that the company will earn ($1.12) per sharMay 31, 2024 | marketbeat.comPassage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship AwardMay 21, 2024 | globenewswire.comOptimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy RatingMay 15, 2024 | markets.businessinsider.comPassage Bio Reports Promising Interim Data in FTD-GRN Treatment TrialMay 15, 2024 | msn.comPassage Bio (NASDAQ:PASG) Price Target Cut to $13.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group lowered their price objective on Passage Bio from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Wednesday.May 15, 2024 | marketbeat.comPassage Bio, Inc. (NASDAQ:PASG) Forecasted to Post Q1 2025 Earnings of ($0.20) Per SharePassage Bio, Inc. (NASDAQ:PASG - Free Report) - Investment analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of Passage Bio in a research report issued on Tuesday, May 14th. Wedbush analyst L. Chico anticipates that the company will post earnings of ($0.20) peMay 15, 2024 | marketbeat.comPASG Stock Earnings: Passage Bio Beats EPS for Q1 2024May 14, 2024 | investorplace.comPassage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsMay 14, 2024 | globenewswire.comPassage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 22, 2024 | finance.yahoo.comPassage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 22, 2024 | globenewswire.comPassage Bio (NASDAQ:PASG) Trading Up 3.1%Passage Bio (NASDAQ:PASG) Trading Up 3.1%March 29, 2024 | marketbeat.comPASG Apr 2024 7.500 callMarch 20, 2024 | finance.yahoo.comPASG Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comPassage Bio, Inc. (NASDAQ:PASG) Expected to Post Q1 2024 Earnings of ($0.33) Per SharePassage Bio, Inc. (NASDAQ:PASG - Free Report) - Equities researchers at Wedbush lifted their Q1 2024 earnings per share (EPS) estimates for shares of Passage Bio in a research note issued on Monday, March 4th. Wedbush analyst L. Chico now anticipates that the company will post earnings per shareMarch 7, 2024 | marketbeat.comPASG Stock Earnings: Passage Bio Beats EPS for Q4 2023March 6, 2024 | investorplace.comPassage Bio, Inc. to Post FY2028 Earnings of $0.05 Per Share, Wedbush Forecasts (NASDAQ:PASG)Passage Bio, Inc. (NASDAQ:PASG - Free Report) - Investment analysts at Wedbush issued their FY2028 earnings per share (EPS) estimates for shares of Passage Bio in a report issued on Monday, March 4th. Wedbush analyst L. Chico expects that the company will post earnings of $0.05 per share for theMarch 6, 2024 | marketbeat.com Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. PASG Media Mentions By Week PASG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PASG News Sentiment▼-0.600.46▲Average Medical News Sentiment PASG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PASG Articles This Week▼51▲PASG Articles Average Week Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALGS News MCRB News ANRO News AVTX News IFRX News DERM News CABA News CDTX News VXRT News RANI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PASG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PASG Stock Alerts